

Confidential & Proprietary

Not Subject to Disclosure Under the Vermont Public Records Act, 1 V.S.A. § 316 *et seq.*, or Otherwise

Pfizer Inc.

66 Hudson Blvd East
New York, NY 10001



June 27, 2023

ATTN: Vermont Attorney General Charity Clark
Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

Re: Notice of Submission of New Drug Report Pursuant to 18 V.S.A. § 4637

To Whom It May Concern,

I am writing to inform the Attorney General's Office of Pfizer, Inc. ("Pfizer")'s submission of new drug reports pursuant to 18 V.S.A. § 4637 for its recently acquired product, Nurtec® ODT ("Nurtec").

On October 3, 2022, Pfizer completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), the original manufacturer of Nurtec. At the time of acquisition, Pfizer was assured that all required transparency reports for Nurtec had been submitted. Legacy Biohaven personnel remained responsible for reporting until April 1, 2023. Pfizer's transparency team, in assuming prospective responsibility for reporting as of that date, were not able to locate Biohaven's transparency records. We have not been able to identify a new prescription drug report for Nurtec, and we cannot confirm that such a report was submitted within thirty days of the product's original launch on March 12, 2020 or whether notice was provided within three days of the product's original launch.

Accordingly, Pfizer has worked as expeditiously as possible to compile the data needed to submit the attached drug reports.

Pfizer is committed to ensuring compliance with Vermont's price transparency law and has worked expeditiously in taking the steps discussed here.

Please do not hesitate to contact me with any questions.

Sincerely,

Laura Topal
Senior Director, US Strategic Pricing